FLT3 and axial length measurement: Nowadays, with targeted therapies, e.g., FLT3-inhibitors in AML [27], tyrosine-kinase inhibitors in ALL [28], or antibody/immunotherapies such as blinatumomab [29] or gemtuzumab/ozogamicin [30], more precise and possibly less toxic or less immunosuppressive therapies for treating AL patients are available and might impact the decision for choosing individual regimens in AL patients with COVID-19.